Announces Presentation Of New Otl-201 Clinical Data In Sanfilippo Syndrome Type A (Mps-Iiia)
05/11/2020 12:55
Nov 5 (Reuters) - Orchard Therapeutics PLC ORTX.O :
* ORCHARD THERAPEUTICS PLC - ANNOUNCES PRESENTATION OF NEW
OTL-201 CLINICAL DATA IN SANFILIPPO SYNDROME TYPE A (MPS-IIIA)
* ORCHARD THERAPEUTICS PLC - PRELIM RESULTS FROM FIRST
PATIENT
TREATED WITH OTL-201 SHOW EVIDENCE OF ENGRAFTMENT OF
GENE-MODIFIED CELLS, AMONG OTHERS
Source text for Eikon: ID:nGNX4XpNJS
Further company coverage: ORTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Orchard Therapeutics
See all newsBrief: Orchard Therapeutics Says Court Of Justice Of England & Wales Sanctioned Scheme Of Arrangement Providing For Acquisition Of Co By Kyowa Kirin Co's Unit
Brief: Orchard Therapeutics Receives U.S. FDA Fast Track Designation For OTL-203 In MPS-IH
Brief: Orchard Therapeutics Says U.S. FDA Advised Co It Does Not Intend To Schedule Advisory Committee Meeting
Orchard Therapeutics rises on buyout deal by Japanese drugmaker
Kyowa Kirin to acquire Orchard Therapeutics for $478 mln